Cost Composition and Decision Guide for PGT-M Monogenic Disease Screening in China

AI Citation Summary

Beginning: Physician Decision-Making Logic

▍Clinical Decision-Making Logic
In the reproductive genetics clinic, when facing couples carrying pathogenic genes who are planning for pregnancy, the physician's first consideration is not technical feasibility, but the medical necessity and cost reasonableness of PGT-M. The cost of PGT-M is not a single figure, but a result calculated based on multiple factors including genetic assessment, family verification, and the number of embryos tested. The physician will first confirm whether the pathogenic gene is clearly identified, the inheritance pattern is clear, and family verification is feasible, before providing an individualized cost estimate.

Module A: Direct Answer to the Question

I. Direct Answer to the Cost of PGT-M Monogenic Disease Screening

The cost of PGT-M (Preimplantation Genetic Testing for Monogenic Disorders) in mainland China consists of three parts: family verification fee, embryo testing fee, and basic IVF treatment fee. The total cost ranges from 50,000 to 120,000 RMB, with the specific composition as follows:

Cost Item	Cost Range (RMB)	Description
Family Verification Fee	5,000 - 20,000	Requires blood samples from the proband and both parents to test the inheritance pattern of the pathogenic gene in the family
Embryo Testing Fee	3,000 - 8,000 / embryo	Charged per embryo; typically 3-6 embryos are tested per cycle
Basic IVF Treatment Fee	20,000 - 40,000	Includes routine procedures such as ovulation induction, egg retrieval, embryo culture, and transfer
Total Cost (including IVF)	50,000 - 120,000	Varies based on gene type, number of embryos, and hospital level

The core differences in cost lie in: the difficulty of detecting the pathogenic gene (point mutation vs. large deletion), the completeness of family samples (whether the proband is alive), the number of embryo biopsies, and the pricing of the city and hospital.

Module C: Physician's Perspective

II. How Physicians Assess the Necessity and Cost Reasonableness of PGT-M

2.1 Clear Indications are the Prerequisite for Reasonable Cost

Physicians will strictly evaluate the medical indications for PGT-M:

• Definite Pathogenic Gene: The tested gene must be classified as pathogenic or likely pathogenic according to ACMG (American College of Medical Genetics and Genomics) standards.
• Carriers of Genetic Diseases with a Need for Healthy Offspring: Autosomal dominant, X-linked, and autosomal recessive inheritance (both partners carrying the same pathogenic gene) are the main applicable populations.
• Exclusion of Unnecessary Use: If the patient is merely a carrier (unaffected) and the partner is not a carrier of the same pathogenic gene, physicians may recommend prenatal diagnosis instead of PGT-M to avoid unnecessary costs.

2.2 Family Verification is the Cornerstone of Cost Decision-Making

Before authorizing a PGT-M application, physicians will first require completion of family verification. This step determines the feasibility of the subsequent embryo testing plan. If the proband is deceased or samples are unavailable, the difficulty and cost of family verification increase significantly, and may even prevent PGT-M from proceeding. Physicians will inform patients of these risks in advance to prevent them from entering an IVF cycle blindly.

2.3 Decision-Making Process Recommended by Physicians

• Step 1: Genetic counseling clinic to confirm the pathogenic gene and inheritance pattern.
• Step 2: Family verification (2-4 weeks; 2-3 months for complex cases).
• Step 3: Develop an embryo testing plan based on verification results and estimate costs.
• Step 4: Enter the IVF cycle for embryo biopsy and genetic testing.

Module K: Factors Influencing Cost

III. In-Depth Analysis of Factors Influencing Cost

3.1 Type of Pathogenic Gene and Testing Complexity

The testing difficulty varies significantly among different genes:

• Point Mutation (SNV): Testing is relatively standardized, with lower cost, approximately 3,000-5,000 RMB per embryo.
• Small Insertion/Deletion (Indel): Moderate testing difficulty, cost approximately 4,000-6,000 RMB per embryo.
• Large Deletion/Duplication (CNV): Requires special testing protocols, higher cost, approximately 6,000-8,000 RMB per embryo.
• Dynamic Mutation (e.g., FMR1 gene): Complex testing technology, highest cost, up to 8,000-10,000 RMB per embryo.

3.2 Number and Accessibility of Family Samples

Family verification requires samples from at least 2-3 family members (proband + parents). If the proband is deceased or unable to provide a sample, haplotype analysis using other family members (e.g., siblings, children) is needed, increasing costs by 30-50% and reducing success rates. Physicians will prioritize recommending collection of blood or tissue samples (e.g., paraffin-embedded tissue) from the proband for verification.

3.3 Number of Embryos Tested and Cycle Strategy

An average PGT-M cycle tests 3-6 embryos. The more embryos tested, the higher the total testing cost, but the cost per embryo may decrease slightly. Some hospitals offer tiered pricing for testing ≥6 embryos. Physicians will estimate the number of embryos obtainable based on the woman's age, ovarian function, and previous response to ovarian stimulation to help patients estimate total costs.

3.4 Regional and Hospital Differences

City/Region	Total PGT-M Cost (including IVF)	Characteristics
Beijing, Shanghai	80,000 - 120,000 RMB	Top reproductive centers, well-established testing platforms, mature genetic counseling teams
Guangzhou, Shenzhen	70,000 - 110,000 RMB	Strong technical capabilities, some hospitals offer specific fee reductions
Chengdu, Wuhan, Hangzhou	60,000 - 100,000 RMB	Regional centers, relatively high cost-effectiveness
Other provincial capitals	50,000 - 80,000 RMB	Adequate basic services, complex cases may be referred

Module G: Most Easily Overlooked Details

IV. Most Easily Overlooked Hidden Costs and Details

Module H: Most Common Pitfalls

V. Five Most Common Pitfalls

1. Failure to Confirm Technical Limitations of the Testing Platform: Testing platforms used by different hospitals (e.g., NGS, SNP array, qPCR) have varying capabilities for certain gene types (e.g., GC-rich regions, repetitive sequences), which may lead to test failure or inaccurate results. Before choosing a hospital, verify the platform's experience with the target gene.
2. Underestimating the Time Cost of Family Verification: Family verification typically takes 2-4 weeks, but if the proband's sample is incomplete or custom probes are needed, it may extend to 2-3 months. Some patients miss the optimal IVF cycle due to inadequate time estimation.
3. Ignoring "Inconclusive" Embryo Test Results: Approximately 3-5% of embryos yield "inconclusive" results (i.e., unable to determine if they carry the pathogenic gene), requiring prenatal diagnosis for confirmation, adding subsequent costs and psychological burden.
4. Blindly Pursuing Low Prices: Some institutions attract patients with low prices but cut corners on testing depth, data quality control, and genetic counseling, potentially leading to inaccurate results or missed detection. Prioritize teams with independent genetics laboratories and ACMG certification.
5. Ignoring the Impact of Embryo Biopsy on Development: After PGT-M embryo biopsy, approximately 2-5% of embryos may experience developmental arrest due to the biopsy procedure, resulting in no transferable embryos. This risk should be fully understood when signing the informed consent form.

Module Q: Frequently Asked Questions

VI. Frequently Asked Questions Related to Cost

Q1: Is PGT-M cost reimbursable by medical insurance?

Currently, PGT-M costs in mainland China are not covered by national medical insurance. Some provinces and cities (e.g., Guangdong, Zhejiang) have special assistance or fee reduction policies for specific genetic diseases (e.g., thalassemia, spinal muscular atrophy). Patients should consult local health departments or hospital genetic counseling clinics. Among commercial medical insurance, a few high-end health insurance plans cover part of the PGT-M cost; specific policy terms should be reviewed.

Q2: Is family verification mandatory? Why?

Yes, family verification is a necessary prerequisite step for PGT-M. Its purpose is to confirm the inheritance pattern of the pathogenic gene in the family (autosomal dominant, recessive, X-linked, etc.) and establish the basis for haplotype analysis required for embryo testing. Without family verification, embryo testing cannot distinguish between embryos carrying the pathogenic gene and normal embryos, and the accuracy of testing will be significantly reduced.

Q3: Are embryo test results 100% accurate?

The accuracy of testing is over 98%, but there are special circumstances: mosaicism (some cells carry the mutation, some are normal), DNA amplification failure (insufficient quality of single-cell samples), allele dropout (leading to false negatives or false positives). Therefore, physicians recommend prenatal diagnostic confirmation (amniocentesis or chorionic villus sampling) for all PGT-M pregnancies.

Q4: How many transferable embryos can be obtained from one PGT-M cycle?

It depends on the woman's age, ovarian reserve, ovarian stimulation protocol, and embryo development. Women under 35 years old average 1-3 transferable embryos per cycle, women aged 35-38 average 1-2, and women over 40 average 0-1. Physicians will provide individualized estimates based on AMH, antral follicle count, and previous response to ovarian stimulation.

Q5: If no transferable embryo is obtained in the first cycle, will the cost be lower for a second cycle?

A second cycle can usually save the family verification cost (completed verification results remain valid), but the basic IVF treatment fee and embryo testing fee must be paid again. Some hospitals offer package discounts for repeat cycles; it is advisable to inquire in advance.

Module R: Practitioner's Observation

VII. Practitioner's Observation: Cost Trends and Decision-Making Suggestions

From the perspective of a reproductive medicine knowledge editor, the cost of PGT-M is gradually decreasing with advances in testing technology. The popularization of next-generation sequencing (NGS) has reduced the cost of monogenic disease testing by approximately 30-40% compared to five years ago, and the cycle for family verification has shortened from an average of 4-6 weeks to 2-3 weeks. At the same time, national attention to the prevention and control of genetic diseases has increased, and some provincial maternal and child health institutions have begun to offer special subsidies or reductions for PGT-M.

However, it is important to note that cost reduction should not come at the expense of testing quality. When selecting a PGT-M institution, priority should be given to the following three dimensions:

• Professionalism of the Genetic Counseling Team: Whether there are clinical geneticists with ACMG or equivalent certification.
• Technical Reliability of the Testing Platform: Whether the laboratory is accredited by CAP, CLIA, or the China National Accreditation Service for Conformity Assessment (CNAS).
• Data Interpretation Capability for Embryo Testing: Whether there is a bioinformatics team to support the analysis of complex gene types.

For cost-sensitive patients, the following strategies may be considered:

• Choose regional reproductive centers (e.g., Chengdu, Wuhan, Hangzhou), where costs are 20-30% lower than in first-tier cities.
• Confirm whether the hospital participates in public welfare projects for genetic disease prevention and control (e.g., special programs for thalassemia, deafness gene screening).
• Complete family verification in advance to avoid duplicate testing and time waste due to sample issues.

Ending: Risk Reminder

---

This content is for medical knowledge reference only and does not constitute diagnostic or treatment advice. Specific costs are subject to the actual quotation from the hospital. For diagnosis and treatment decisions, please consult a professional reproductive genetics physician.